iLIVER最新文献

{"title":"Recalibrating the evidence level in hepatocellular carcinoma: Integrating efficacy and effectiveness of immunotherapy","authors":"Han Wu , Xin-Fei Xu , Jia-Hao Law, Tian Yang","doi":"10.1016/j.iliver.2025.100200","DOIUrl":"10.1016/j.iliver.2025.100200","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 4","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review","authors":"Liping Yan ,&nbsp;Peng Tao","doi":"10.1016/j.iliver.2025.100186","DOIUrl":"10.1016/j.iliver.2025.100186","url":null,"abstract":"<div><div>Breast cancer is the most prevalent malignancy in women globally, with metastatic disease accounting for approximately 90 % of breast cancer-related deaths. The development of breast cancer liver metastases in patients not only significantly reduces survival rates but also severely impairs quality of life. This review systematically examines therapeutic advances in the treatment of breast cancer liver metastases from 2010 to 2023, focusing on novel targeted agents (CDK4/6 inhibitors, PI3K/mTOR pathway inhibitors), immune checkpoint inhibitors, and local interventions. We provide evidence-based recommendations to optimize personalized treatment strategies and improve clinical outcomes for patients with breast cancer liver metastases.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100186"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated multi-omics analysis identifies TPX2 as a potential prognostic and immunological biomarker in hepatocellular carcinoma","authors":"Hui Peng ,&nbsp;Yong-peng Wei ,&nbsp;Xin-bo Liu ,&nbsp;Yu Wang ,&nbsp;Jian-yong Yuan","doi":"10.1016/j.iliver.2025.100184","DOIUrl":"10.1016/j.iliver.2025.100184","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, characterized by aggressive behavior, limited therapeutic efficacy, and poor patient outcomes. TPX2, a microtubule-associated protein essential for mitotic spindle formation, has been associated with tumorigenesis in various cancers. However, its functional significance in shaping the immune landscape and influencing treatment sensitivity in HCC remains insufficiently elucidated.</div></div><div><h3>Methods</h3><div>We conducted an integrated multi-omics analysis using transcriptomic (TCGA, GTEx, GEO), proteomic (CPTAC), and pharmacogenomic (GDSC, PRISM, CTRP) datasets to assess TPX2 expression patterns in HCC. We performed differential expression analysis, survival analysis, Cox regression, and nomogram construction. Co-expression modules were identified via weighted gene co-expression network analysis (WGCNA), followed by GO and KEGG enrichment analyses. The correlations between TPX2 expression levels and immune and genomic features were examined, and drug sensitivity associations were evaluated.</div></div><div><h3>Results</h3><div>TPX2 was consistently overexpressed in HCC tissues and associated with advanced tumor stage, higher grade, and poor survival. WGCNA revealed TPX2-enriched modules linked to cell cycle and DNA replication pathways. High TPX2 expression levels were correlated with immunosuppressive features, including reduced lymphocyte infiltration, lower IFN-γ response, and increased expression levels of immune checkpoint molecules (PD-1, CTLA-4, HAVCR2). TPX2-high tumors also exhibited greater genomic instability. Drug sensitivity analysis indicated resistance to several chemotherapeutics, but increased sensitivity to mitotic inhibitors and targeted agents.</div></div><div><h3>Conclusions</h3><div>TPX2 is a key driver of proliferation and immune evasion in HCC, potentially serving as a diagnostic and prognostic biomarker to guide treatment strategies involving mitotic- or immune-based therapies.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100184"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144888771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technical advances and application strategies in anatomical hepatic resection based on Laennec's capsule","authors":"Shuai Yan ,&nbsp;Jinzhu Wu","doi":"10.1016/j.iliver.2025.100182","DOIUrl":"10.1016/j.iliver.2025.100182","url":null,"abstract":"<div><div>Laennec's capsule is a dense fibrous membrane that has recently been confirmed to exist across the entire liver surface, Glissonean pedicles, and major hepatic veins, forming a continuous fibrous system. Minimally invasive anatomical liver resection based on Laennec's capsule-guided dissection leverages natural avascular planes to enable safe and efficient resection. This approach significantly reduces intraoperative bleeding, improves surgical precision and R0 resection rates, and contributes to better long-term survival in patients.</div><div>This review discusses the anatomical concept of Laennec's capsule and its clinical application in minimally invasive anatomical liver resection. It outlines the advantages, limitations, and strategic use of various preoperative navigation techniques; analyses the indications for intrafascial/extrafascial Glissonean approaches and the technical aspects of their selection; analyses outer/inner dissection of Laennec's capsule around the hepatic veins according to the type of tumour; and proposes technical refinements based on outflow control and precision surgery. Finally, it explores the debate about the origins of Laennec's capsule and suggests directions for future bastardization and research.</div><div>This review aims to provide hepatobiliary surgeons with a comprehensive reference based on recent technical advances and application strategies for Laennec's capsule-based anatomical liver resection.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100182"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress on Laennec's capsule guidance for hepatobiliary surgery","authors":"Decai Yu,&nbsp;Leizhou Xia","doi":"10.1016/j.iliver.2025.100183","DOIUrl":"10.1016/j.iliver.2025.100183","url":null,"abstract":"<div><div>Anatomic resection remains a fundamental principle in the surgical management of hepatobiliary diseases, whether performed through traditional open surgery or advanced minimally invasive approaches such as laparoscopic or robotic-assisted techniques. However, a universally accepted and clearly defined anatomical framework for intraoperative anatomical delineation remains lacking. The growing clinical adoption of Laennec membrane-guided anatomical strategies has been associated with notable improvements in surgical efficacy and anatomical precision. This approach facilitates clear identification of anatomical layers, enhances visualization of key landmarks, and enables the execution of precise anatomical resections. As a result, it promotes standardization and reproducibility across surgical procedures. This article presents a comprehensive review of operative techniques and critical technical considerations for Laennec membrane-guided anatomical procedures in hepatobiliary surgery, establishing a three-dimensional anatomical foundation for clinical practice to support the standardization and broader adoption of precision-oriented hepatobiliary surgical methodologies.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144916376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing techniques, navigating liver resection complexity, and mastering the learning curve for safe expansion of minimally invasive hepatectomy","authors":"Yoshikuni Kawaguchi","doi":"10.1016/j.iliver.2025.100180","DOIUrl":"10.1016/j.iliver.2025.100180","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100180"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nucleic acid therapeutics for liver diseases: A decade of technological convergence and clinical challenges","authors":"Yufei Pan ,&nbsp;Mingyue Pan ,&nbsp;Yuanzheng Huang ,&nbsp;Baoping Lian ,&nbsp;Yutian Feng ,&nbsp;Juan Liu ,&nbsp;Xiaoxuan Liu","doi":"10.1016/j.iliver.2025.100178","DOIUrl":"10.1016/j.iliver.2025.100178","url":null,"abstract":"<div><div>This review synthesizes a decade of advancements in nucleic acid therapeutics for liver diseases, incorporating bibliometric analysis and translational evaluation. The field has evolved from foundational viral vector engineering to precision genome editing and RNA-based modulation, with advancements in CRISPR-Cas9 and innovations in non-viral delivery systems. Our analysis highlights the concentrated research efforts made in metabolic disorders and hepatocellular carcinoma, and reveals an emerging emphasis on multifactorial pathologies. Although clinical milestones highlight important advancements in targeting strategies, significant challenges remain in immune compatibility and preclinical translation. The integration of computational modeling, human-relevant disease models, and combinatorial strategies places nucleic acid therapies in a unique position to tackle the evolving global liver disease burden through mechanism-driven interventions.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100178"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144517883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-driven multimodal fusion of tongue images and clinical indicators for identifying MAFLD patients at risk of coronary artery disease: An exploratory study","authors":"Jingjing Zhang ,&nbsp;Song Feng ,&nbsp;Jian Xue ,&nbsp;Chao Zhou ,&nbsp;Shuangnan Fu ,&nbsp;Pengcheng Liu ,&nbsp;Zhaoyun He ,&nbsp;Man Gong ,&nbsp;Hui Feng ,&nbsp;Shuangnan Zhou ,&nbsp;Ning Zhang","doi":"10.1016/j.iliver.2025.100181","DOIUrl":"10.1016/j.iliver.2025.100181","url":null,"abstract":"<div><h3>Background and aims</h3><div>Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with coronary artery disease (CAD), but existing risk assessment tools lack precision and scalability. We developed an AI-driven multimodal framework integrating traditional Chinese medicine (TCM) tongue-based diagnosis with clinical biomarkers to stratify CAD risk in MAFLD.</div></div><div><h3>Methods</h3><div>In this cross-sectional study with prospective data collection, which comprised 1073 MAFLD patients stratified by CAD status (MAFLD without CAD, <em>n</em> = 942; MAFLD with CAD, <em>n</em> = 131), baseline characteristics were compared using chi-square tests for categorical variables and Mann-Whitney U tests for continuous variables, with <em>p</em> &lt; 0.05 considered significant. We developed two distinct deep learning models: Model-1 (non-invasive) using ResNet18 combined tongue image features with demographic and comorbidity data, and Model-2 (comprehensive) incorporated blood biomarkers alongside the features used in Model-1. Multimodal feature fusion was achieved through a dedicated cross-attention network. Model performance was rigorously evaluated using 10-fold cross-validation, with area under the curve (AUC), sensitivity, and specificity as primary metrics. Focal loss was employed to address class imbalance.</div></div><div><h3>Results</h3><div>The coexistence of CAD was associated with significantly higher rates of hypertension, diabetes, and familial cardiovascular history in patients with MAFLD (<em>p</em> &lt; 0.001), along with distinct metabolic profiles: elevated systemic inflammation (neutrophil-lymphocyte ratio), advanced fibrosis (FIB-4), elevated fasting glucose levels, and attenuated hepatic inflammation (ALT and AST). Model-1 achieved an AUC of 0.858 (sensitivity 0.778, specificity 0.908), while Model-2 demonstrated superior discrimination (AUC 0.933), particularly in tertiary care.</div></div><div><h3>Conclusion</h3><div>Our AI-driven dual-model framework addresses the critical unmet need for CAD identification in MAFLD patients, providing a community-scalable screening tool (Model-1) and a precision clinical assessment model (Model-2), while offering empirical support for TCM tongue diagnosis. Pending external validation to confirm its generalizability, this approach may serve as a cost-efficient non-invasive screening strategy for this high-risk population.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100181"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma","authors":"Jianan Jiang ,&nbsp;Yinbiao Cao ,&nbsp;Shang Gao ,&nbsp;Yanqin Hu ,&nbsp;Shizhong Yang ,&nbsp;Haowen Tang","doi":"10.1016/j.iliver.2025.100187","DOIUrl":"10.1016/j.iliver.2025.100187","url":null,"abstract":"<div><div>With the global incidence of hepatocellular carcinoma (HCC) on the rise, precise staging has become critical for guiding treatment decisions and improving long-term outcomes. The Barcelona Clinic Liver Cancer (BCLC) staging system, widely used for HCC classification, incorporates factors such as Child–Pugh A or B liver function, tumor size and number, absence of cancer-related symptoms, and lack of vascular invasion or extrahepatic metastasis. For intermediate-stage HCC, transarterial chemoembolization (TACE) remains the globally recommended standard. However, the substantial heterogeneity in tumor burden and liver function among patients means that not all individuals benefit equally from TACE. As a result, a uniform treatment approach is insufficient. Preserving liver function is now recognized as equally important as achieving high objective response rates, with the ultimate goal of prolonging overall survival. In response, researchers have proposed advanced stratification methods for stage B HCC to optimize therapeutic outcomes. While these stratification criteria remain under debate, there is a growing shift from TACE-centric strategies toward personalized targeted therapies for specific subpopulations. This review explores advanced stratification concepts, evaluates corresponding treatment strategies, analyzes ongoing clinical trials, and assesses their potential to transform the management of intermediate-stage HCC—while also outlining future directions for its treatment.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100187"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The application of liver cancer organoids in tumour precision medicine: A comprehensive review","authors":"Jiaye Mo ,&nbsp;Da Gong ,&nbsp;Mei Zhai ,&nbsp;Jintao Yang ,&nbsp;Zhike Li ,&nbsp;Meilong Wu ,&nbsp;Xuesong Deng ,&nbsp;Xiaoyong Dai","doi":"10.1016/j.iliver.2025.100179","DOIUrl":"10.1016/j.iliver.2025.100179","url":null,"abstract":"<div><div>Liver cancer is a leading cause of cancer-related death worldwide, and its complexity and heterogeneity pose considerable challenges to conventional treatment. In recent years, the rise of organoid technology has provided new perspectives and tools for precision medicine in oncology. The use of high-fidelity organoids capable of recapitulating patients' genotypic and phenotypic features can further facilitate personalised treatment. In this review, we discuss 1) the advantages of liver cancer organoids as disease models over traditional models; 2) the origin and establishment of liver cancer organoids; 3) the application of liver cancer organoids technology in tumour precision medicine; 4) the technical tools of liver cancer-derived organoids; and 5) current solutions for the deficiencies and challenges of liver cancer organoids. This review should provide both a deeper understanding of the research progress and application prospects of liver cancer organoids, as well as theoretical support and practical guidance for more complete integration of liver cancer research and precision medicine.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"4 3","pages":"Article 100179"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}